Linagliptin alleviates fatty liver disease in diabetic db/db mice

Figure 7 The mean proportions of hepatocytes with different densities of lipid droplets in linagliptin-treated and placebo-treated db/db mice. The percent of hepatocytes with high density of lipid droplets (more than 15 droplets per cell) is reduced in linagliptin-treated mice compared to placebo-treated mice (hep, hepatocyte, L < 5, less than 5 lipid droplets per cell, L > 15, more than 15 lipid droplets per cell, ^aP < 0.05).